logo
Search orAI Icon𝛼SK
bullish

Jiangsu Hengrui Medicine

Jiangsu Hengrui Pharma A/H Listing - Recent Updates and Thoughts on A/H Premium

706 Views10 Apr 2025 09:48
Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing. In this note, we talk about the likely A/H premiums.
What is covered in the Full Insight:
  • Introduction
  • Recent Updates
  • Quick Peer Comparison
  • Thoughts on Valuations and A/H Premium
  • Summary
Boomeranged on Tue, 6 May 2025 12:08
The company has now filed its PHIP and is said to be pre-marketing with an aim to launch the deal in the coming week. Although it would have to competed with CATL if it does launch next week.
Logo
Sumeet Singh
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.7

x